BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Fluidigm Corporation 5.6M-Share IPO Prices At $13.50; Low End Of Prior Estimate


2/10/2011 7:20:20 AM

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Fluidigm Corporation today announced the pricing of its initial public offering of 5,558,333 shares of its common stock at a price to the public of $13.50 per share. The shares of common stock have been approved to trade on The NASDAQ Global Market under the symbol “FLDM.”

Deutsche Bank Securities Inc. and Piper Jaffray & Co. are acting as joint book-running managers for the offering. Cowen and Company LLC and Leerink Swann acted as co-managers. Fluidigm has granted the underwriters an option to purchase up to an additional 833,750 shares of common stock to cover over-allotments, if any.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on February 9, 2011.

This offering is being made solely by means of a prospectus, copies of which may be obtained from: Deutsche Bank Securities Inc., Attn: Prospectus Department, 100 Plaza One, Floor 2, Jersey City, NJ 07311, or by calling (800) 503-4611 or emailing a request to prospectusrequest@list.db.com or by contacting Piper Jaffray & Co. at 800 Nicollet Mall, Suite 800, Minneapolis, MN 55402, by calling 1-800-747-3924.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Fluidigm

Fluidigm develops, manufactures and markets microfluidic systems for growth markets in the life science and agricultural biotechnology, or Ag-Bio, industries. Fluidigm’s proprietary microfluidic systems consist of instruments and consumables, including chips and reagents. These systems are designed to significantly simplify experimental workflow, increase throughput and reduce costs, while providing the excellent data quality demanded by customers. Fluidigm actively markets three microfluidic systems including eight different commercial chips to leading pharmaceutical and biotechnology companies, academic institutions, diagnostic laboratories and Ag-Bio companies.

For more information, please visit www.fluidigm.com

“Fluidigm” and the Fluidigm logo are trademarks or registered trademarks of Fluidigm.

Contact: Fluidigm Corporation Howard High, 650-266-6081 (office) 510-786-7378 (mobile) howard.high@fluidigm.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES